Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate Lumryz met all primary and key secondary ...

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press ...

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the ...

Alkermes (NASDAQ:ALKS) executives highlighted a strong start to 2026 and the completion of the Avadel Pharmaceuticals acquisition during the company’s first-quarter earnings call, pointing to accelera ...

View Alkermes Public Limited Company ALKS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago. These figures are ...

Alkermes PLC (ALKS) on Tuesday reported a first-quarter loss of $66.5 million, after reporting a profit in the same period a year earlier.

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Alkermes is transitioning into an integrated neuroscience and sleep medicine company. Click here to see why ALKS stock is a ...

(Reuters) -Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals in a deal valued at up to $2.1 billion, gaining an approved sleep-disorder treatment and expanding into the sleep medicine ...

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was ...